Evaluation of a Protocol for Multidisciplinary Management of Acute Cholecystitis.

December 10, 2020 updated by: Fundacion Miguel Servet

Evaluation of the Applicability and Effectiveness of a Protocol for the Multidisciplinary Management of Acute Cholecystitis

Acute cholecystitis is a complex disease and its management is sometimes controversial. Two main factors contribute to its complexity: the patient's surgical risk and the possibility of concomitant choledocholithiasis. The design of a multidisciplinary protocol between the services of Gastroenterology and Surgery aims to harmonize its management and to adapt it to the most recent guidelines. As it concerns more than one department, it is crucial to analyze its compliance and effectiveness.

Study Overview

Status

Unknown

Conditions

Detailed Description

Adult patients attending the emergency department and diagnosed with acute cholecystitis will be asked to participate. Those considered not suitable for surgery will be admitted in a medical department and assigned to conservative treatment or cholecystostomy, according to their acute cholecystitis severity. In patients suitable for surgery, risk of concomitant choledocholithiasis will be assessed and patients will be assigned to low risk or intermediate-high risk. The latter will be admitted in a medical department, and choledocholithiasis will be ruled out and treated if present. The former will be offered cholecystectomy or cholecystostomy according to their surgical risk and acute cholecystitis severity. A flowchart with extended information is attached.

PRIMARY OBJECTIVES

• To harmonize the management of acute cholecystitis with a multidisciplinary protocol based on the most recent guidelines.

SECONDARY OBJECTIVES

  • To analyze the compliance with this protocol.
  • To evaluate the validity of the criteria used in the decision-making process.
  • To assess the morbidity and mortality of different groups of patients according to the selected treatment, severity of cholecystitis and baseline characteristics of the patient.
  • To estimate the resource use in each group of patients.
  • To compare current data with a previous period.
  • To adapt and modify the protocol according the study results. INCLUSION CRITERIA
  • Patients aged 18 or older who agree to participate (an informed consent signature is required)
  • Patients attended in the emergency department of our hospital and diagnosed with acute cholecystitis according to the Tokyo criteria.

EXCLUSION CRITERIA

  • Patients under 18 years or patients who refuse to participate in the study
  • Patients diagnosed with acute cholangitis during admission for other causes.

Study Type

Observational

Enrollment (Anticipated)

600

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Contact Backup

Study Locations

    • Navarra
      • Pamplona, Navarra, Spain, 31008
        • Recruiting
        • Complejo Hospitalario de Navarra
        • Contact:
        • Contact:
        • Principal Investigator:
          • Federico Bolado Concejo, MD, PhD
        • Sub-Investigator:
          • Marian Casi Villaroya, MD
        • Sub-Investigator:
          • Lucas Blázquez Lautre, MD
        • Sub-Investigator:
          • Pablo Sánchez Acedo, MD
        • Sub-Investigator:
          • Cristina Saldaña Dueñas, MD
        • Sub-Investigator:
          • Belen González de la Higuera Carnicer, MD
        • Sub-Investigator:
          • Erika Borobio Aguilar, MD
        • Sub-Investigator:
          • Amaia Arrubla Gamboa, MD
        • Sub-Investigator:
          • Bruno Camarero Triana, MD

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years and older (ADULT, OLDER_ADULT)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Sampling Method

Non-Probability Sample

Study Population

Patients attended in the emergency department of CHN and diagnosed with acute cholecystitis.

Description

Inclusion Criteria:

  • Patients aged 18 or older who agree to participate (an informed consent signature is required)
  • Patients attended in the emergency department of our hospital and diagnosed with acute cholecystitis according to the Tokyo criteria.

Exclusion Criteria:

  • Patients under 18 years or patients who refuse to participate in the study
  • Patients diagnosed with acute cholangitis during admission for other causes.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

Cohorts and Interventions

Group / Cohort
Patients unfit for Surgery with mild-moderate acute cholecyst
Conservative treatment (antibiotics, etc). EUS-guided gallbladder drainage will be considered in recurrent acute cholecystitis and in patients with no improvement in 48-72h after admission.
Patients unfit for Surgery with severe acute cholecystitis
Percutaneous cholecystostomy or Endoscopic Ultrasound (EUS)-guided cholecystostomy (the latter is not 24/7 available). Palliative care may also be considered in patients with very serious conditions and low life expectancy.
Patients suitable for Surgery with high and intermediate risk

Admission in Gastroenterology Department. antibiotic treatment. Close follow-up of posible AC complications. Once choledocholithiasis is solved or ruled our, the patient will be considered for same-admission cholecystectomy or programmed cholecystectomy.

  • High risk: Endoscopic Retrograde Cholangiopancreatography (ERCP) will be performed.
  • Intermediate risk: EUS or Magnetic Resonance Cholangiopancreatography prior to consider ERCP.
Patients suitable for Surgery with low risk

Admission in Surgery Department. According to the AC severity:

  • Mild-moderate AC: check de ASA/Charlson comorbidity index.
  • ASA I-II/Charlson <6: laparoscopic cholecystectomy
  • ASA > =III/Charlson >=6: close follow-up 24-48h. Consider laparoscopic cholecystostomy (if no improvement is achieved)
  • Severe AC: consider Intensive Care Unit admission. Percutaneous cholecystectomy.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Inclusion rate
Time Frame: During inclusion period
Rate of patients with AC diagnosis registered in the study
During inclusion period
Protocol compliance
Time Frame: During inclusion period
Rate of patients with complete protocol compliance
During inclusion period
Morbidity in the different subtypes of patients
Time Frame: three months after hospital discharge
length of hospital stay, need for unplanned readmissions, recurrent cholecystitis
three months after hospital discharge
Mortality in the different subtypes of patients
Time Frame: three months after hospital discharge
90-day disease-specific mortality
three months after hospital discharge

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Protocol compliance failure
Time Frame: every 3 months throughout study completion (up to 1 year)
Identify causes of protocol compliance failure
every 3 months throughout study completion (up to 1 year)
Evaluate the technical success
Time Frame: During inclusion period (up to 1 year)
Evaluate clinical success and adverse events of the different treatments.
During inclusion period (up to 1 year)
Evaluate the accuracy in the diagnosis
Time Frame: three months after hospital discharge or after ERCP
Evaluate the accuracy of Magnetic Resonance Cholangiopancreatography (MRCP) and EUS in the diagnosis of concomitant choledocholithiasis
three months after hospital discharge or after ERCP

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Principal Investigator: Federico Bolado Concejo, MD, PhD, Complejo Hospitalario de Navarra

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (ACTUAL)

July 1, 2020

Primary Completion (ANTICIPATED)

July 1, 2022

Study Completion (ANTICIPATED)

January 1, 2023

Study Registration Dates

First Submitted

September 2, 2020

First Submitted That Met QC Criteria

September 2, 2020

First Posted (ACTUAL)

September 10, 2020

Study Record Updates

Last Update Posted (ACTUAL)

December 14, 2020

Last Update Submitted That Met QC Criteria

December 10, 2020

Last Verified

December 1, 2020

More Information

Terms related to this study

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

UNDECIDED

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Acute Cholecystitis

3
Subscribe